18421326. Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors simplified abstract (Regeneron Pharmaceuticals, Inc.)

Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors

Organization Name

Regeneron Pharmaceuticals, Inc.

Inventor(s)

Neelroop Parikshak of Tarrytown NY (US)

Giovanni Coppola of Tarrytown NY (US)

Jonathan Marchini of Tarrytown NY (US)

Benjamin Geraghty of Tarrytown NY (US)

Sahar Gelfman of Tarrytown NY (US)

Tanima De of Tarrytown NY (US)

Veera Rajagopal of Tarrytown NY (US)

Ernst Mayerhofer of Tarrytown NY (US)

Nilanjana Banerjee of Tarrytown NY (US)

Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors - A simplified explanation of the abstract

This abstract first appeared for US patent application 18421326 titled 'Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors

The present disclosure involves treating subjects with a stroke or at risk of developing a stroke by administering a 1,4-alpha-glucan-branching enzyme (GBE1) inhibitor to the subject.

• The innovation involves using a GBE1 inhibitor to treat stroke patients or those at risk of stroke.
• The inhibitor targets a specific enzyme to prevent or reduce the risk of stroke.
• This treatment method offers a new approach to managing stroke and its associated risks.
• By inhibiting GBE1, the inhibitor may help improve outcomes for stroke patients.
• The innovation may lead to advancements in stroke treatment and prevention strategies.

Potential Applications: - Treatment of stroke patients - Prevention of strokes in high-risk individuals - Research in stroke management and prevention

Problems Solved: - Addressing the need for more effective stroke treatments - Providing a targeted approach to stroke prevention - Improving outcomes for stroke patients

Benefits: - Enhanced treatment options for stroke patients - Reduced risk of stroke in high-risk individuals - Potential for improved quality of life for stroke survivors

Commercial Applications: Title: Innovative Stroke Treatment Using GBE1 Inhibitor This technology could have commercial applications in pharmaceuticals, healthcare, and research industries. It may lead to the development of new stroke treatments and prevention methods, potentially creating market opportunities for companies in the medical field.

Questions about Stroke Treatment Using GBE1 Inhibitor: 1. How does the GBE1 inhibitor specifically target stroke risk factors? The GBE1 inhibitor targets the enzyme responsible for branching glucose molecules, which plays a role in stroke development.

2. What sets this treatment approach apart from traditional stroke management strategies? This treatment approach focuses on inhibiting a specific enzyme to address stroke risks, offering a novel method in stroke care.

Original Abstract Submitted

The present disclosure generally relates to the treatment of subjects having a stroke or at risk of developing a stroke by administering a 1,4-alpha-glucan-branching enzyme (GBE1) inhibitor to the subject.